New Stock News | Jiangxi Biotechnology Submits Documents to the Hong Kong Stock Exchange for the Third Time

According to the disclosure by the Hong Kong Stock Exchange on May 4th, Jiangxi Institute of Biological Products Co., Ltd. (referred to as Jiangxi Bio) has submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CICC and CMSC International as joint sponsors. It is known that Jiangxi Bio had previously submitted listing applications to the Hong Kong Stock Exchange on October 26, 2025, and April 11, 2025. The prospectus shows that Jiangxi Bio is the largest provider and exporter of human tetanus antitoxin (human TAT) in China, and also a comprehensive anti-serum platform provider. According to Frost & Sullivan data, the company is the largest provider of human TAT in China and globally, with market shares of 65.8% and 36.6% based on sales volume in 2024. In 2025, the company's total sales volume of human TAT was 29.9 million doses, with 13.5 million doses sold in China and 16.4 million doses exported to overseas markets.